Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors

Pharmacological Research

Volumn 43, Issue 5, 2001, Pages 453-461

  Serebruany, Victor L ^a,b   Gurbel, Paul A ^a,b   O'Connor, Christopher M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Depression; Platelets; Selective serotonin reuptake inhibitors

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ANTIDEPRESSANT AGENT; CD31 ANTIGEN; CD9 ANTIGEN; COLLAGEN; DRUG METABOLITE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; NORSERTRALINE; PADGEM PROTEIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VITRONECTIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION;

EID: 0034954784     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0817     Document Type: Article

References (63)

1. Depression following myocardial infarction - Iimpact on 6-month survival
2. Going home after a heart attack. Depression is also a risk factor
3. Major depressive disorders in coronary artery disease
4. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS)
5. Depression and 18-month prognosis after myocardial infarction
6. Preclinical pharmacology of sertraline: A potent and specific inhibitor of serotonin reuptake
7. The serotonin hypothesis of depression
8. Platelet-derived serotonin, the endothelium, and cardiovascular disease
9. Exaggerated platelet reactivity in major depression
10. Effects of serotonin on platelets and blood vessels
11. Alterations of plasma factor of platelet aggregation and 5-HT untake in depression
12. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors
13. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors
14. New insights into the mechanisms of platelet adhesion and aggregation
15. Factors influencing platelet aggregation in the whole blood
16. Flow cytometric measurement of platelet function and reticulated platelets
17. Characterization of an in vitro platelet function analyzer, PFA-100™
18. Rapid platelet-function assay. An automated and quantitative cartridge-based method
19. Heterogeneity of platelet aggregation and major surface receptor expression in patients presenting with acute myocardial infarction
20. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. The GUSTO III platelet study
21. Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction
22. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction
23. (H) Imipramine binding in human platelets: A new biochemical parameter in depression
24. Platelet serotonergic indices in major depression: Up-regulation of 5-HT2A receptors unchanged by antidepressant treatment
25. Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients
26. Platelet monoamine oxidase activity in elderly depressed out patients
27. Classification of patients with affective disorders using platelet monoamine oxidase activity, serum melatonin and post-dexamethasone cortisol
28. Platelet monoamine oxidase activity in patients with winter seasonal affective disorder
29. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease
30. Sertraline: A new antidepressant
31. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients
32. Platelet 5HT accumulation in depressive illness
33. Serotonin 5-HT2 receptor binding on blood platelets - A peripheral marker for depression
34. Platelet serotonin markers and depressive symptomatology
35. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: Relationship to symptomatology and medication
36. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients
37. Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression
38. Platelet imidazoline receptors and regulatory G proteins in patients with major depression
39. The effect of clinical outcome on platelet G proteins of major depressed patients
40. Alteration by a plasma factor(s) of platelet aggregation in unmedicated unipolar depressed patients
41. Further characterization of the inhibition of platelet aggregation by a plasma factor(s) in unmedicated unipolar depressed patients
42. Blood coagulation and platelet aggregation in major depression
43. Adrenaline-induced platelet aggregation in depressed patients and control subjects
44. The platelet serotonergic system in depression and following sertraline treatment
45. Abnormal platelet aggregation associated with fluoxetine therapy
46. Bruising associated with the use of fluoxetine
47. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors
48. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury
49. Effects of serotonin reuptake inhibitors on hemostasis
50. Effects of serotonin on platelet activation in whole blood
51. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin?
52. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins
53. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor
54. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression
55. Antithrombocytic effectiveness of magnesium
56. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina
57. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
58. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation
59. Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats
60. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers
61. Clinical overview of serotonin reuptake inhibitors
62. Depression and the course of coronary artery disease
63. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction